Expertise in
7
conditions

Dr. Adekunle Odunsi

Oncology
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 
Expertise in
7
conditions
University Of Chicago Medical Center
5841 S Maryland Ave, 
Chicago, IL 

Overview

Adekunle Odunsi is an Oncologist in Chicago, Illinois. Dr. Odunsi is highly rated in 7 conditions, according to our data. His top areas of expertise are Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, Testicular Yolk Sac Tumor, and Desmoplastic Small Round Cell Tumor.

His clinical research consists of co-authoring 9 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Oncology

Licenses

Obstetrics & Gynecology in NY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

University of Chicago Medical Center
5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 As Monotherapy Or In Combination With Either Nivolumab Or Pembrolizumab In HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Enrollment Status: Active_not_recruiting
Publish Date: April 07, 2026
Intervention Type: Genetic
Study Phase: Phase 1
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Enrollment Status: Terminated
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drug: NC762
Study Phase: Phase 1/Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Phase II Study of Recombinant Vaccinia-NY-ESO-1 (rV-NY-ESO-1) and Recombinant Fowlpox-NY-ESO-1 (rF-NY-ESO-1) in Patients With Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma Whose Tumors Express NY-ESO-1 or LAGE-1 Antigen
Enrollment Status: Completed
Publish Date: October 04, 2023
Intervention Type: Biological
Study Phase: Phase 2
3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
3D-PREDICT REGISTRY: 3D Prediction of Patient-specific Response Using Ex Vivo Interrogation of Live Cells From Tumors
Enrollment Status: Unknown
Publish Date: March 24, 2023
Intervention Type: Diagnostic test
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
A Multi-national, Open-label, Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Administrations of NKR-2 in Patients With Different Metastatic Tumor Types (THINK - THerapeutic Immunotherapy With NKR-2)
Enrollment Status: Unknown
Publish Date: September 19, 2019
Intervention Type: Biological
Study Drug: NKR-2 Cells
Study Phase: Phase 1/Phase 2
View 5 Less Clinical Trials

8 Total Publications

Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Fidelity of human ovarian cancer patient-derived xenografts in a partially humanized mouse model for preclinical testing of immunotherapies.
Journal: Journal for immunotherapy of cancer
Published: October 16, 2020
Similar Doctors
Expertise in
27
conditions
Dr. Sonali Smith
Oncology
Expertise in
27
conditions
Dr. Sonali Smith
Oncology

University Of Chicago Medical Center

5841 S Maryland Ave, 
Chicago, IL 
 (0.1 miles away)
773-834-2895
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sonali Smith is an Oncologist in Chicago, Illinois. Dr. Smith is highly rated in 27 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

Leo I. Gordon
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
Expertise in
33
conditions
Dr. Leo I. Gordon
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
866-587-4322
Experience:
53+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Leo Gordon is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Gordon has been practicing medicine for over 53 years is highly rated in 33 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
25
conditions
Dr. Reem Karmali
Hematology | Oncology
Expertise in
25
conditions
Dr. Reem Karmali
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
866-587-4322
Experience:
20+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Reem Karmali is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Karmali has been practicing medicine for over 20 years is highly rated in 25 conditions, according to our data. Her top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Hodgkin Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Adekunle Odunsi

How do I make an appointment with Dr. Adekunle Odunsi?

You can book an appointment with Dr. Adekunle Odunsi by calling their office at 773-702-1000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Adekunle Odunsi a top-rated expert for Virilizing Ovarian Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Adekunle Odunsi is classified as an Distinguished expert for Virilizing Ovarian Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Adekunle Odunsi specialize in?

While Dr. Adekunle Odunsi is a Oncology, they have specific expertise in Virilizing Ovarian Tumor, Ovarian Carcinosarcoma, and Testicular Yolk Sac Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Adekunle Odunsi participate in research or clinical trials?

Yes. Dr. Adekunle Odunsi has published 8 articles and abstracts on conditions like Virilizing Ovarian Tumor. You can view a list of Dr. Adekunle Odunsi's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Adekunle Odunsi accept my insurance?

Dr. Adekunle Odunsi accepts most major insurance plans, including Aetna and Humana. We recommend calling the office directly at 773-702-1000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Odunsi's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile